With full membership, watch our educational and editorial videos, search the site, receive our newsletters, join discussions, download slides and much more.
The treatment options for oral anticoagulation therapy are constantly evolving. Join our expert panel, Drs. Graham Turpie, Jessica L. Mega, Jeffrey Weitz, as they discuss the new data and clinical implications of new anticoagulant medications for patients with ACS
Variations on chromosome 4q25 are associated with atrial fibrillation (AF). If you had a family history of AF, would you be tested? Dr. Christopher Granger who has such a personal history underwent testing. He discusses the role of genetics in the management of patients with or at risk for AF.
Join Drs Topol, Califf, Hollenberg and Levy has they list the latest cardiovascular clinical trials demonstrating a genetically targeted response to treatment.
The 2008 AHA meeting included a special session on "Personalized Genomics: Ready for Prime Time?" Read Dr Wang's article on recent genetic findings in CAD, AF and HF while Drs Ballantyne, Granger, Herrington, Mega and Topol address related AHA presentations and the clinical utility of genetic data in CVD management.
Variations in the VKORC1 and CYP2C9 genes alter warfarin metabolism. In August 2007, the FDA label for warfarin was updated to highlight genetic testing to predict warfarin response. David Herrington addresses the utility of genetic testing to more rapidly optimize warfarin dosing.
Underdiagnosed and undertreated, PAD is a growing health and economic burden in an increasingly aging population. Routine screening and effective management strategies can reduce long-term adverse outcomes. Join Drs Bhatt, Steg, Hirsch, and Hiatt as they discuss treatment guidelines for prevention and treatment of PAD.
Genetic variations have been associated with an increased risk for type 2 diabetes (T2D) – a condition strongly influenced by lifestyle factors. In a literal case of personalized medicine, Dr Geoffrey Ginsburg discusses the role of genetic testing in the assessment of patients, including himself, at risk for T2D.
Cardiovascular (CV) disease is the single leading cause of death in the United States. Multiple risk factors such as hypertension, diabetes, obesity, and dyslipidemia contribute to multiple pathophysiologic/neurohormonal processes that affect the development of CV disease. This program will review current and emerging approaches to CV risk management. CME Provider: The Academy for Healthcare Education, Inc. Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Variations on chromosome 4q25 are associated with atrial fibrillation (AF). If you had a family history of AF, would you be tested? Dr. Christopher Granger who has such a personal history underwent testing. He discusses the role of genetics in the management of patients with or at risk for AF.
The 2008 AHA meeting included a special session on "Personalized Genomics: Ready for Prime Time?" Read Dr Wang's article on recent genetic findings in CAD, AF and HF while Drs Ballantyne, Granger, Herrington, Mega and Topol address related AHA presentations and the clinical utility of genetic data in CVD management.
The following test-and-teach case is an educational activity modeled on the interactive grand rounds approach. The questions within the activity are designed to test your current knowledge. After each question, you will be able to see whether you answered correctly and will then read evidence-based information that supports the most appropriate answer choice. Please note that these questions are designed to challenge you; you will not be penalized for answering the questions incorrectly. At the end of the case, there will be a short post-test assessment based on material covered in the activity.
Genetic findings that affect the course of diseases have been increasing geometrically. Cardiology is one of the specialties that has benefited from recent discoveries. David Danar, MD, Scientific Director, MedscapeCME, interviewed John P. Kane, MS, MD, PhD, about the role of genetics in determining the risk for and management of heart disease.